Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) Stock Competitors & Peer Comparison
See PHAT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PHAT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PHAT | $11.95 | +4.46% | 953.1M | -8.13 | -$1.47 | N/A |
| VRTX | $479.00 | +0.34% | 121.6B | 25.45 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $667.17 | +1.70% | 68.7B | 14.62 | $45.63 | +0.54% |
| ARGX | $888.82 | -3.20% | 55.3B | 80.22 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $188.07 | -0.61% | 40B | -26.60 | -$7.07 | N/A |
| RVMDW | $9.55 | +0.53% | 39.8B | -2.27 | -$4.15 | N/A |
| ALNY | $278.40 | +2.44% | 37.2B | 50.16 | $5.55 | N/A |
| ONC | $325.90 | +0.00% | 34.8B | 72.91 | $4.47 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
PHAT vs VRTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, VRTX has a market cap of 121.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while VRTX trades at $479.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas VRTX's P/E ratio is 25.45. In terms of profitability, PHAT's ROE is +0.39%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, PHAT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check VRTX's competition here
Verona Pharma plc (NASDAQ: VRNA)
PHAT vs VRNA Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas VRNA's P/E ratio is -102.80. In terms of profitability, PHAT's ROE is +0.39%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, PHAT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check VRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
PHAT vs REGN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, REGN has a market cap of 68.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while REGN trades at $667.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas REGN's P/E ratio is 14.62. In terms of profitability, PHAT's ROE is +0.39%, compared to REGN's ROE of +0.14%. Regarding short-term risk, PHAT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check REGN's competition here
argenx SE (NASDAQ: ARGX)
PHAT vs ARGX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ARGX trades at $888.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ARGX's P/E ratio is 80.22. In terms of profitability, PHAT's ROE is +0.39%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, PHAT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
PHAT vs SGEN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas SGEN's P/E ratio is -57.19. In terms of profitability, PHAT's ROE is +0.39%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, PHAT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
PHAT vs RVMD Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while RVMD trades at $188.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas RVMD's P/E ratio is -26.60. In terms of profitability, PHAT's ROE is +0.39%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, PHAT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
PHAT vs RVMDW Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, RVMDW has a market cap of 39.8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while RVMDW trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas RVMDW's P/E ratio is -2.27. In terms of profitability, PHAT's ROE is +0.39%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, PHAT is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
PHAT vs ALNY Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ALNY has a market cap of 37.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ALNY trades at $278.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ALNY's P/E ratio is 50.16. In terms of profitability, PHAT's ROE is +0.39%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, PHAT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ALNY's competition here
BeOne Medicines AG (NASDAQ: ONC)
PHAT vs ONC Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ONC has a market cap of 34.8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ONC trades at $325.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ONC's P/E ratio is 72.91. In terms of profitability, PHAT's ROE is +0.39%, compared to ONC's ROE of +0.12%. Regarding short-term risk, PHAT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ONC's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
PHAT vs ROIV Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ROIV trades at $34.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ROIV's P/E ratio is -35.69. In terms of profitability, PHAT's ROE is +0.39%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, PHAT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
PHAT vs INCY Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while INCY trades at $118.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas INCY's P/E ratio is 15.98. In terms of profitability, PHAT's ROE is +0.39%, compared to INCY's ROE of +0.29%. Regarding short-term risk, PHAT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
PHAT vs BNTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, BNTX has a market cap of 23B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while BNTX trades at $91.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas BNTX's P/E ratio is -19.72. In terms of profitability, PHAT's ROE is +0.39%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, PHAT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
PHAT vs INSM Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, INSM has a market cap of 22.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while INSM trades at $104.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas INSM's P/E ratio is -18.21. In terms of profitability, PHAT's ROE is +0.39%, compared to INSM's ROE of -1.30%. Regarding short-term risk, PHAT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
PHAT vs UTHR Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, UTHR has a market cap of 22.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while UTHR trades at $527.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas UTHR's P/E ratio is 19.49. In terms of profitability, PHAT's ROE is +0.39%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, PHAT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
PHAT vs MRNA Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, MRNA has a market cap of 22.1B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while MRNA trades at $55.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas MRNA's P/E ratio is -6.83. In terms of profitability, PHAT's ROE is +0.39%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, PHAT is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MRNA's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
PHAT vs BGNE Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas BGNE's P/E ratio is -22.55. In terms of profitability, PHAT's ROE is +0.39%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, PHAT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
PHAT vs DNA-WT Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, PHAT's ROE is +0.39%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, PHAT is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check DNA-WT's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
PHAT vs NBIX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, NBIX has a market cap of 17.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while NBIX trades at $176.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas NBIX's P/E ratio is 25.49. In terms of profitability, PHAT's ROE is +0.39%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, PHAT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check NBIX's competition here
Genmab A/S (NASDAQ: GMAB)
PHAT vs GMAB Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while GMAB trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas GMAB's P/E ratio is 20.72. In terms of profitability, PHAT's ROE is +0.39%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, PHAT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check GMAB's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
PHAT vs BBIO Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, BBIO has a market cap of 16.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while BBIO trades at $84.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas BBIO's P/E ratio is -22.49. In terms of profitability, PHAT's ROE is +0.39%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, PHAT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BBIO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
PHAT vs JAZZ Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, JAZZ has a market cap of 16B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while JAZZ trades at $255.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas JAZZ's P/E ratio is 19.86. In terms of profitability, PHAT's ROE is +0.39%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, PHAT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
PHAT vs ASND Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ASND has a market cap of 15.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ASND trades at $253.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ASND's P/E ratio is -104.72. In terms of profitability, PHAT's ROE is +0.39%, compared to ASND's ROE of -56.42%. Regarding short-term risk, PHAT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
PHAT vs EXEL Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, EXEL has a market cap of 14B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while EXEL trades at $55.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas EXEL's P/E ratio is 16.71. In terms of profitability, PHAT's ROE is +0.39%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, PHAT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check EXEL's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
PHAT vs MDGL Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, MDGL has a market cap of 12.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while MDGL trades at $551.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas MDGL's P/E ratio is -43.07. In terms of profitability, PHAT's ROE is +0.39%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, PHAT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MDGL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
PHAT vs KRTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas KRTX's P/E ratio is -28.09. In terms of profitability, PHAT's ROE is +0.39%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, PHAT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check KRTX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
PHAT vs AXSM Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, AXSM has a market cap of 12.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while AXSM trades at $238.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas AXSM's P/E ratio is -62.24. In terms of profitability, PHAT's ROE is +0.39%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, PHAT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check AXSM's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
PHAT vs ARWR Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ARWR has a market cap of 12B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ARWR trades at $85.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ARWR's P/E ratio is -39.78. In terms of profitability, PHAT's ROE is +0.39%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, PHAT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
PHAT vs BMRN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while BMRN trades at $60.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas BMRN's P/E ratio is 28.98. In terms of profitability, PHAT's ROE is +0.39%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, PHAT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BMRN's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
PHAT vs RNAM Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas RNAM's P/E ratio is -17.39. In terms of profitability, PHAT's ROE is +0.39%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, PHAT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RNAM's competition here
Bio-Techne Corporation (NASDAQ: TECH)
PHAT vs TECH Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, TECH has a market cap of 11.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while TECH trades at $71.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas TECH's P/E ratio is 36.91. In terms of profitability, PHAT's ROE is +0.39%, compared to TECH's ROE of +0.05%. Regarding short-term risk, PHAT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TECH's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
PHAT vs KRYS Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, KRYS has a market cap of 10.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while KRYS trades at $351.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas KRYS's P/E ratio is 47.03. In terms of profitability, PHAT's ROE is +0.39%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, PHAT is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
PHAT vs SMMT Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, SMMT has a market cap of 10.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while SMMT trades at $13.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas SMMT's P/E ratio is -8.19. In terms of profitability, PHAT's ROE is +0.39%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, PHAT is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check SMMT's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
PHAT vs CYTK Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CYTK has a market cap of 10B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CYTK trades at $80.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CYTK's P/E ratio is -13.83. In terms of profitability, PHAT's ROE is +0.39%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, PHAT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CYTK's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
PHAT vs HALO Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while HALO trades at $81.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas HALO's P/E ratio is 17.64. In terms of profitability, PHAT's ROE is +0.39%, compared to HALO's ROE of +1.26%. Regarding short-term risk, PHAT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check HALO's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
PHAT vs RXDX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas RXDX's P/E ratio is -56.47. In terms of profitability, PHAT's ROE is +0.39%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, PHAT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
PHAT vs ABVX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ABVX has a market cap of 9.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ABVX trades at $128.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ABVX's P/E ratio is -67.09. In terms of profitability, PHAT's ROE is +0.39%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, PHAT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
PHAT vs IONS Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, IONS has a market cap of 9.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while IONS trades at $55.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas IONS's P/E ratio is -32.53. In terms of profitability, PHAT's ROE is +0.39%, compared to IONS's ROE of -0.59%. Regarding short-term risk, PHAT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check IONS's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
PHAT vs NUVL Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas NUVL's P/E ratio is -21.79. In terms of profitability, PHAT's ROE is +0.39%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, PHAT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check NUVL's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
PHAT vs KYMR Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while KYMR trades at $110.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas KYMR's P/E ratio is -31.18. In terms of profitability, PHAT's ROE is +0.39%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, PHAT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
PHAT vs CRNX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CRNX has a market cap of 8.9B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CRNX trades at $83.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CRNX's P/E ratio is -16.35. In terms of profitability, PHAT's ROE is +0.39%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, PHAT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CRNX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
PHAT vs PRAX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, PRAX has a market cap of 8.8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while PRAX trades at $315.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas PRAX's P/E ratio is -23.62. In terms of profitability, PHAT's ROE is +0.39%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, PHAT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PRAX's competition here
Alkermes plc (NASDAQ: ALKS)
PHAT vs ALKS Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ALKS has a market cap of 8.8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ALKS trades at $52.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ALKS's P/E ratio is 55.51. In terms of profitability, PHAT's ROE is +0.39%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, PHAT is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ALKS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
PHAT vs IMGN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas IMGN's P/E ratio is -111.55. In terms of profitability, PHAT's ROE is +0.39%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, PHAT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
PHAT vs PTGX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, PTGX has a market cap of 8.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while PTGX trades at $135.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas PTGX's P/E ratio is -74.90. In terms of profitability, PHAT's ROE is +0.39%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, PHAT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PTGX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
PHAT vs SYRE Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, SYRE has a market cap of 8.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while SYRE trades at $100.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas SYRE's P/E ratio is -48.10. In terms of profitability, PHAT's ROE is +0.39%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, PHAT is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
PHAT vs TGTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while TGTX trades at $55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas TGTX's P/E ratio is 19.16. In terms of profitability, PHAT's ROE is +0.39%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, PHAT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TGTX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
PHAT vs BPMC Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas BPMC's P/E ratio is -51.58. In terms of profitability, PHAT's ROE is +0.39%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, PHAT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
PHAT vs APGE Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while APGE trades at $134.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas APGE's P/E ratio is -31.01. In terms of profitability, PHAT's ROE is +0.39%, compared to APGE's ROE of -0.33%. Regarding short-term risk, PHAT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check APGE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
PHAT vs IMVT Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while IMVT trades at $40.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas IMVT's P/E ratio is -15.01. In terms of profitability, PHAT's ROE is +0.39%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, PHAT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check IMVT's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
PHAT vs CERE Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CERE's P/E ratio is -16.47. In terms of profitability, PHAT's ROE is +0.39%, compared to CERE's ROE of -0.72%. Regarding short-term risk, PHAT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CERE's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
PHAT vs PCVX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while PCVX trades at $55.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas PCVX's P/E ratio is -8.07. In terms of profitability, PHAT's ROE is +0.39%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, PHAT is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PCVX's competition here
Metsera, Inc. (NASDAQ: MTSR)
PHAT vs MTSR Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas MTSR's P/E ratio is -23.58. In terms of profitability, PHAT's ROE is +0.39%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, PHAT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MTSR's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
PHAT vs IBRX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, IBRX has a market cap of 7.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while IBRX trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas IBRX's P/E ratio is -8.22. In terms of profitability, PHAT's ROE is +0.39%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, PHAT is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check IBRX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
PHAT vs RYTM Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, RYTM has a market cap of 7.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while RYTM trades at $106.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas RYTM's P/E ratio is -33.91. In terms of profitability, PHAT's ROE is +0.39%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, PHAT is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check RYTM's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
PHAT vs MIRM Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, MIRM has a market cap of 7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while MIRM trades at $114.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas MIRM's P/E ratio is -8.39. In terms of profitability, PHAT's ROE is +0.39%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, PHAT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
PHAT vs COGT Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, COGT has a market cap of 6.9B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while COGT trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas COGT's P/E ratio is -19.17. In terms of profitability, PHAT's ROE is +0.39%, compared to COGT's ROE of -0.83%. Regarding short-term risk, PHAT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check COGT's competition here
Merus N.V. (NASDAQ: MRUS)
PHAT vs MRUS Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas MRUS's P/E ratio is -17.05. In terms of profitability, PHAT's ROE is +0.39%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, PHAT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
PHAT vs ACLX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ACLX's P/E ratio is -28.27. In terms of profitability, PHAT's ROE is +0.39%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, PHAT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
PHAT vs RETA Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas RETA's P/E ratio is -66.29. In terms of profitability, PHAT's ROE is +0.39%, compared to RETA's ROE of +0.47%. Regarding short-term risk, PHAT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RETA's competition here
Erasca, Inc. (NASDAQ: ERAS)
PHAT vs ERAS Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ERAS has a market cap of 6.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ERAS trades at $18.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ERAS's P/E ratio is -20.29. In terms of profitability, PHAT's ROE is +0.39%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, PHAT is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
PHAT vs CGON Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CGON has a market cap of 6.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CGON trades at $73.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CGON's P/E ratio is -31.55. In terms of profitability, PHAT's ROE is +0.39%, compared to CGON's ROE of -0.23%. Regarding short-term risk, PHAT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CGON's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
PHAT vs XENE Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, XENE has a market cap of 6.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while XENE trades at $65.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas XENE's P/E ratio is -14.00. In terms of profitability, PHAT's ROE is +0.39%, compared to XENE's ROE of -0.49%. Regarding short-term risk, PHAT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check XENE's competition here
Belite Bio, Inc (NASDAQ: BLTE)
PHAT vs BLTE Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while BLTE trades at $158.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas BLTE's P/E ratio is -84.72. In terms of profitability, PHAT's ROE is +0.39%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, PHAT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check BLTE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
PHAT vs PTCT Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, PTCT has a market cap of 6.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while PTCT trades at $75.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas PTCT's P/E ratio is -32.53. In terms of profitability, PHAT's ROE is +0.39%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, PHAT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check PTCT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
PHAT vs CNTA Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CNTA's P/E ratio is -22.63. In terms of profitability, PHAT's ROE is +0.39%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, PHAT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
PHAT vs LGND Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, LGND has a market cap of 6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while LGND trades at $297.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas LGND's P/E ratio is 35.67. In terms of profitability, PHAT's ROE is +0.39%, compared to LGND's ROE of +0.16%. Regarding short-term risk, PHAT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
PHAT vs SRRK Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, SRRK has a market cap of 5.9B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while SRRK trades at $48.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas SRRK's P/E ratio is -13.63. In terms of profitability, PHAT's ROE is +0.39%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, PHAT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
PHAT vs CDTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CDTX's P/E ratio is -19.77. In terms of profitability, PHAT's ROE is +0.39%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, PHAT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
PHAT vs ABCM Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, PHAT's ROE is +0.39%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, PHAT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
PHAT vs ISEE Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ISEE's P/E ratio is -22.44. In terms of profitability, PHAT's ROE is +0.39%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, PHAT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ISEE's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
PHAT vs TVTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while TVTX trades at $56.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas TVTX's P/E ratio is -257.64. In terms of profitability, PHAT's ROE is +0.39%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, PHAT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
PHAT vs APLS Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas APLS's P/E ratio is 38.35. In terms of profitability, PHAT's ROE is +0.39%, compared to APLS's ROE of +0.40%. Regarding short-term risk, PHAT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check APLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
PHAT vs TERN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas TERN's P/E ratio is -51.41. In terms of profitability, PHAT's ROE is +0.39%, compared to TERN's ROE of -0.20%. Regarding short-term risk, PHAT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
PHAT vs DFTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while DFTX trades at $42.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas DFTX's P/E ratio is N/A. In terms of profitability, PHAT's ROE is +0.39%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, PHAT is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check DFTX's competition here
Veradermics, Incorporated (NYSE: MANE)
PHAT vs MANE Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while MANE trades at $111.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas MANE's P/E ratio is -35.45. In terms of profitability, PHAT's ROE is +0.39%, compared to MANE's ROE of -0.84%. Regarding short-term risk, PHAT is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
PHAT vs FOLD Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas FOLD's P/E ratio is -161.00. In terms of profitability, PHAT's ROE is +0.39%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, PHAT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check FOLD's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
PHAT vs CRSP Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CRSP has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CRSP trades at $46.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CRSP's P/E ratio is -9.15. In terms of profitability, PHAT's ROE is +0.39%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, PHAT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CRSP's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
PHAT vs AKRO Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas AKRO's P/E ratio is -14.57. In terms of profitability, PHAT's ROE is +0.39%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, PHAT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check AKRO's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
PHAT vs EWTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, EWTX has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while EWTX trades at $41.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas EWTX's P/E ratio is -25.06. In terms of profitability, PHAT's ROE is +0.39%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, PHAT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check EWTX's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
PHAT vs ALPN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ALPN's P/E ratio is -101.52. In terms of profitability, PHAT's ROE is +0.39%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, PHAT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ALPN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
PHAT vs CAI Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CAI trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CAI's P/E ratio is -85.97. In terms of profitability, PHAT's ROE is +0.39%, compared to CAI's ROE of +0.06%. Regarding short-term risk, PHAT is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CAI's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
PHAT vs DNTH Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while DNTH trades at $104.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas DNTH's P/E ratio is -25.30. In terms of profitability, PHAT's ROE is +0.39%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, PHAT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check DNTH's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
PHAT vs ACAD Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ACAD trades at $25.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ACAD's P/E ratio is 12.45. In terms of profitability, PHAT's ROE is +0.39%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, PHAT is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
PHAT vs DYN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, DYN has a market cap of 4.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while DYN trades at $25.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas DYN's P/E ratio is -7.96. In terms of profitability, PHAT's ROE is +0.39%, compared to DYN's ROE of -0.58%. Regarding short-term risk, PHAT is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check DYN's competition here
Opthea Limited (NASDAQ: OPT)
PHAT vs OPT Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas OPT's P/E ratio is -1.52. In terms of profitability, PHAT's ROE is +0.39%, compared to OPT's ROE of +1.18%. Regarding short-term risk, PHAT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check OPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
PHAT vs MRTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas MRTX's P/E ratio is -4.82. In terms of profitability, PHAT's ROE is +0.39%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, PHAT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check MRTX's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
PHAT vs VKTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while VKTX trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas VKTX's P/E ratio is -8.42. In terms of profitability, PHAT's ROE is +0.39%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, PHAT is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check VKTX's competition here
Celcuity Inc. (NASDAQ: CELC)
PHAT vs CELC Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CELC has a market cap of 4B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CELC trades at $82.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CELC's P/E ratio is -21.09. In terms of profitability, PHAT's ROE is +0.39%, compared to CELC's ROE of -2.45%. Regarding short-term risk, PHAT is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CELC's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
PHAT vs CPRX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CPRX's P/E ratio is 12.30. In terms of profitability, PHAT's ROE is +0.39%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, PHAT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CPRX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
PHAT vs ELVN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ELVN has a market cap of 3.8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ELVN trades at $52.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ELVN's P/E ratio is -31.58. In terms of profitability, PHAT's ROE is +0.39%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, PHAT is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
PHAT vs RYZB Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas RYZB's P/E ratio is -57.86. In terms of profitability, PHAT's ROE is +0.39%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, PHAT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check RYZB's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
PHAT vs DNLI Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while DNLI trades at $23.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas DNLI's P/E ratio is -8.18. In terms of profitability, PHAT's ROE is +0.39%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, PHAT is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check DNLI's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
PHAT vs CBAY Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas CBAY's P/E ratio is -32.81. In terms of profitability, PHAT's ROE is +0.39%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, PHAT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check CBAY's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMSW)
PHAT vs NAMSW Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, NAMSW has a market cap of 3.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while NAMSW trades at $19.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas NAMSW's P/E ratio is -10.75. In terms of profitability, PHAT's ROE is +0.39%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, PHAT is more volatile compared to NAMSW. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check NAMSW's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
PHAT vs ADPT Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while ADPT trades at $22.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas ADPT's P/E ratio is -41.74. In terms of profitability, PHAT's ROE is +0.39%, compared to ADPT's ROE of -0.24%. Regarding short-term risk, PHAT is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check ADPT's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
PHAT vs LEGN Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while LEGN trades at $19.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas LEGN's P/E ratio is -28.34. In terms of profitability, PHAT's ROE is +0.39%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, PHAT is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check LEGN's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
PHAT vs SWTX Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas SWTX's P/E ratio is -13.78. In terms of profitability, PHAT's ROE is +0.39%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, PHAT is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check SWTX's competition here
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
PHAT vs NAMS Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, NAMS has a market cap of 3.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while NAMS trades at $30.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas NAMS's P/E ratio is -19.01. In terms of profitability, PHAT's ROE is +0.39%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, PHAT is more volatile compared to NAMS. This indicates higher risk in terms of short-term price fluctuations for PHAT.Check NAMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
PHAT vs RCUS Comparison July 2026
Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PHAT stands at 953.1M. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, PHAT is priced at $11.95 on the NASDAQ, while RCUS trades at $27.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PHAT currently has a P/E ratio of -8.13, whereas RCUS's P/E ratio is -8.56. In terms of profitability, PHAT's ROE is +0.39%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, PHAT is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for PHAT.Check RCUS's competition here